Episode 42
Why Aren’t We Immortal? What Bowhead Whales Can Teach Us About Ageing
A bowhead whale can live for more than 200 years. How does its body hold up for that long? Daphna Stern speaks with Dr Mirre Simons, an evolutionary biologist at the University of Sheffield who studies why some animals age faster than others.
Dr Simons co-authored a study in Nature that points to one possible answer: bowhead whale cells are unusually good at repairing damaged DNA. Our own cells make a version of one of the proteins that helps the whale do this.
The conversation explores why large animals get far less cancer than their size alone would predict, a puzzle known as Peto’s paradox. Daphna and Dr Simons also discuss when a cell’s response to stress might help or harm, and what animal studies of intermittent fasting and rapamycin can tell us about human ageing. They look at whether telomeres or a single test score can tell us how fast we are ageing, and discuss new research that found a shift towards longer lipid chains with age in humans and other species.
About the guest
Dr Mirre J. P. Simons
School of Biosciences, University of Sheffield, UK
Dr Simons is an evolutionary biologist and senior lecturer at the University of Sheffield. He earned his PhD at the University of Groningen in the Netherlands. His lab uses fruit flies and compares findings across species to understand why animals age differently and what those differences might teach us about human ageing. His research on diet and ageing has been supported by a Sir Henry Dale Fellowship from Wellcome and the Royal Society. He co-authored the bowhead whale DNA repair study in Nature and the study on lipid chain length and ageing in Nature Aging.
Links
* Dr Mirre Simons at the University of Sheffield
Papers
DNA repair in the long-lived bowhead whale | Nature (2025)
Why the body loses its ability to regulate itself with age | Ageing Research Reviews (2026)
The integrated stress response and lifespan in fruit flies | PNAS (2026)
Dietary restriction and longevity across fruit fly species | EMBO Reports (2026)
Does reproduction come at the cost of survival? Evidence from birds | eLife (2025)
Rapamycin and survival after infection in mice | GeroScience (2023)
Lipid chain length and ageing across species | Nature Aging (2026)
Chapters
00:00 Welcome and the Bowhead Whale
01:44 Why Study Ageing in Animals?
03:42 How Does Evolution Explain Ageing?
06:54 How Do Bowhead Whales Repair Damaged DNA?
10:02 The Human and Whale Versions of CIRBP
13:02 Peto’s Paradox and Cancer Risk in Large Animals
17:26 Can DNA Repair Backfire?
21:18 The Integrated Stress Response
26:54 Intermittent Fasting: Meal Timing or Eating Less?
30:35 Refeeding After Dietary Restriction
31:50 Dietary Variety vs Consistency
32:49 Rapamycin and mTOR Basics
34:33 Rapamycin and Survival After Infection in Animals
36:08 What Would Human Rapamycin Trials Need to Show?
37:17 Can Telomeres Tell Us How Fast We Are Ageing?
40:58 What Do Telomeres Actually Do?
43:13 Can One Number Capture Biological Age?
45:27 How Lipid Chain Length Changes With Age
47:43 Do Longer Lipid Chains Contribute to Ageing?
51:12 Next Steps for Lipid Research Across Species
54:26 The Future of Longevity Research
57:14 Rapid-Fire Questions
58:56 Closing Reflections
Transcript
Foreign.
Welcome to Beyond Longevity, the podcast that explores not just how we age, but how we can build a longer, healthier future for ourselves.
A bowhead whale can live for more than 200 years.
What I wanted to know from my guest today was how its body holds up for that long.
Dr. Mirre Simons is a biologist at the University of Sheffield.
He studies why some animals age faster than others.
The Royal Society has helped fund his work on one part of the puzzle, the link between what animals eat and how fast they age.
Dr. Mirra was part of a team that looked for clues in the whale's cells.
Their findings were published in Nature, one of the world's leading scientific journals.
And one clue for the whale's long life may be the way it repairs damaged DNA.
Our own cells already make a version of a prot routine that helps the whale do those repairs.
Could the whale teach us how to make better use of it?
Hi, Dr Mirre.
Welcome to Beyond Longevity.
You're an evolutionary biologist and senior lecturer at the University of Sheffield, and you've trained in Groningen in the Netherlands, and your research has been supported by Wellcome and the Royal Society.
You study animals age so differently and whether understanding those differences could help us live longer, healthier lives.
What first drew you to the question of why some animals live so much longer than others?
Speaker B:So originally, when I was training for my PhD or actually also my master's, I was mostly concerned with trade offs.
So this is like asking if you do one thing, you can do another thing.
And then you think, okay, there might be limited energy to spend on maintaining your body over doing reproduction or other things.
This is quite closely related to aging.
So that's how I got interested in aging.
Aging is supposedly the ultimate trade off.
But then later I changed my mind.
Speaker A:Why in animals?
Speaker B:Oh, so why animal and not human, you mean?
Speaker A:Yes,.
Speaker B:Humans are also animals.
So in.
In that sense, yeah.
I've always been interested in epidemiology, though, because we can learn a lot from this.
I've been a subject in sort of human type research.
I've never done actual human research myself.
The reason to use animals is mostly because we can study them in the wild in terms of evolutionary biology.
This allows us to look at things that we would normally maybe not be able to look at in human populations.
Also, there's a value in understanding the general biology rather than just focusing on our own.
Also, if you want to measure lifespan, which now is the main subject of, like, the main phenotype we measure, humans are hard.
Right?
So you can get historical Data.
But to do anything experimental is close to impossible.
Speaker A:And it's really great you've made it on the podcast today, because I think you're quite busy today, as I'm sure you're every day.
But later, you're giving an online session at the University of Sheffield for prospective bioscience students.
And I think the title is, which I love, why Are we not the Biology of Aging?
So, before we explore the animals that some of them live for centuries, I want to ask you a very basic question.
Why do we age at all?
What stops the body from just continually maintaining and repairing itself?
Speaker B:The most ultimate explanation for this is that there's causes of mortality that you as an organism cannot fully intrinsically control, right?
So there'll be things that you can partially control, like contracting disease.
But this is quite stochastic, right?
So you can know that you always encounter this disease.
Then there's also accidents.
So animals will just die from an accident, including ourselves.
There can also be predation.
So these things, although they can be controlled intrinsically somewhat, so you can say, like, I'll sit here and avoid predation, they cannot fully be controlled that way.
This means that if you have a steady population, a population will always decrease in size due to these causes of mortality, which means that selection.
So the evolutionary pressures that are acting on, let's say, maintaining ourselves, will decrease with age.
So I sometimes say to my students, if I lecture to them, I say, so each and.
But this is a hypothetical example.
I can say to them, okay, each and every one of you here may carry a mutation that will, like, instantly kill you at 150 years old.
But we never see that mutation because no human lives till 150 years old, right?
So that makes it intuitive.
Although we know that that hypothetical example is probably not true.
It is an accumulation of all small effects.
You can think in the genome.
It can also be wear and tear.
It can be loads of things that make it mostly close to impossible to maintain.
This is the classic evolutionary explanation.
There's some thinking now that maybe simplifies this idea a little bit, where you say, okay, when life is evolving, it needs to do certain things that are not compatible with maintaining something forever, right?
So if you would be a rock, you'll have erosion.
But if you can avoid erosion and not do anything and sit still, you might be able to maintain that same state for a very long time.
Close to not infinity, but very close.
In biology, things need to move.
They need to fuel in and out.
Reproduction needs to happen.
Lots of stuff needs to happen.
Which more or less makes life and aging maybe more or less the same thing.
Which means it's hard to live forever.
Yeah.
And thank you for reminding.
I need to do this this afternoon.
Speaker A:Sorry.
Speaker B:That's fine.
No, I enjoy, I enjoy it.
It's fun actually.
But.
Speaker A:It's a great title.
I love it.
You know how to capture the attention of the students, that's for sure.
Let's look at an animal that makes our own lifespan, even if it were 150 years, look quite modest.
The bowhead whale.
You were part of a study investigating how these animals maintain their DNA and they can live for I think more than 200 years.
What are these whales managing to do that we as humans seem to struggle with?
Speaker B:Yeah.
So this was a study that was done or led by the University of Rochester, by Vera and Andre's lab.
It was great.
Like what they more or less did is in simple terms is ask what is so different about bowhead whale biology compared to other animals.
And what they saw is that a couple of things, the thing they focused on mostly is that there's a higher expression of a protein that's cold induced protein, possibly related to these whales living in cold water.
Possibly, but it's the protein curb, this is a higher level of expression, way higher.
So they picked this up because it's highly expressed.
Then they did loads of work to find that this protein is actually connected to a DNA pair.
So DNA repair is much less prone to errors in bowhead whale samples.
And you can do the genetics and find out that this is partially due to this protein.
Then when we came in, we tested, then we took this sort of evolutionary innovation that Vera and colleagues found in the bowhead whale and we took this same protein and we put it in a food fly.
So we only study food flies, they live short.
We can measure lifespan, we can do the genetics.
Whale.
So my post hook, he cloned the DNA, he put it in the fly, we do the transgenics.
Now we have a fly that can express this protein and we can induce it.
Yes or no.
So it's experimentally very well controlled.
And then we can measure lifespan.
Right.
So it's asking we take a very distant evolutionary innovation, we put this in a completely different animal and we see what happens.
And what happened is they live ever so slightly longer.
It's a robust effect.
And also if we radiate these flies using X rays, so this damages DNA, they actually are more robust to this.
If we overexpress this protein, which suggests, yes, it's probably has something to do with DNA repair, but there's quite a bit more to do to actually find all the underlying mechanism.
But it was quite interesting for me as well because we're thinking like, oh, is DNA repair really key?
And I, I haven't actually focused lots on that and we just like took it, we collaborated on it and it seemed to do what was predicted, which was really cool.
And also it means perhaps like for my own research now, I think actually I'm more interested in that sort of DNA maintenance repair type work.
So we're doing some things on it, but actually we need to click into gear with that a little bit.
It's.
Yeah, it was fun to do.
Speaker A:So I think the protein is the CIRBP protein, right?
Speaker B:Yes.
Speaker A:So there's another.
Not another part of the experiment I think we should explain just to clarify it, humans naturally produce this protein too.
And in your fly experiment, you tested the version found in whales and the version in humans.
And both versions, if I understand it correctly, extended lifespan in the flies.
Right.
So what does that tell us for us humans?
Speaker B:I think in terms of, for the work, I think it means the more you have of this protein, the better.
Actually, if you looked at the total protein levels that were produced in the fly, they were relatively equivalent between the human and the whale protein.
And also in Vera's lab, they showed that it's probably not the specific whale form that is better, its form is actually resulting in more protein.
So you just have more of this protein, which could mean that.
I'm not saying you should do this, but it could mean that if humans have a higher level of this protein, they might have slightly better DNA repair.
You can think like initial translational.
It's not necessarily my field, but you could think where DNA repair is very important in certain DNA repair defects that you can't easily repair with gene therapy.
That could be interesting for longevity, ultimately it could also be interesting, but for proof of principle in terms of that DNA bears possibly quite key in longevity.
That in itself is quite valuable if you look at possible down the line therapeutics.
Right.
So we are building this knowledge foundation space that can be used to then apply to human longevity.
Speaker A:But improved DNA repair in human cells does not really equal to longer human life.
Speaker B:No.
But I guess from my surprise, in a way from doing the fly work, and there's also some like the doing the mouse word.
Now, I'm not showing what's coming out of that, but it does show that possibly DNA pair is also important in the fly.
It does not equate A longer lifespan in human.
It does show that maybe in general in animals.
This is a mechanism that we knew possibly was important.
It maybe went out of fashion a little bit, this mechanism to study it and now it's getting again appreciated.
So it could be, if you think about what's limiting a human lifespan, this can be many things.
One of them could be DNA pair.
It could also be for particular people.
I don't know.
We could find out certain people actually have higher loads of somatic mutations which would help and those therapeutics could possibly in the future maybe not so distant, maybe distant future help human longevity.
Yeah.
Speaker A:So this is related to another research you've been involved with cancer because obviously cancer has to do with the mutations of cells and a whale has so many more cells than a mouse or a human being and lives so much longer.
But the Pito's paradox which you've discussed from different angles says that cancer risk doesn't simply increase in proportion to its size or lifespan.
Can you tell the listeners a little bit about that?
Speaker B:Yes.
So this is a relatively old paradox.
It's called Peter's paradox by the guy that like proposed this first time.
And it's simply stating that if you are bigger and you have more cells, but you have the same amount of damage in each cell, your chance of one of these cells going haywire becoming pre malignant or malignant.
So causing cancer is increasing with your size.
Like it should be proportional to your size.
Actually not directly proportional because it like it scales in an exponential fashion.
But we observe, so the observation across animals, we observe more or less that with bigger size actually the cancer risk maybe ever goes slightly down compared to the prediction.
Even so it's completely contrary to the prediction.
It doesn't follow the rule at all.
There's been some recent discussion on it.
The idea would be okay, it should scale directly with body mass.
Now some people in comparative biology have found it increases maybe ever so slightly.
If you screen the literature in a different way, that cancer risk does increase ever so slightly with body mass, but it never increases at as much as Peter's paradox predicts.
Right.
So in that difference must mean long lived animals have more mechanisms that allow them to avoid cells going into the wrong direct.
One of these mechanisms can be DNA repair or DNA maintenance mechanisms or just being less vulnerable to the damage falling on your DNA.
It can also be, and it's being.
Although I'm not an oncologist, I don't like know anything really about cancer.
But I'm interested because there's a Recent shift away from the idea that somatic mutations are all the drivers of cancer.
Right.
It's also the environment that these cells are in.
The intercell communication that might suppress a single cell that maybe has the tendency to become malignant to then not do it.
And maybe actually this maybe is one of the solutions and interesting solutions that bigger animals use is actually the cell environment where these premalignant cells are in.
It suppresses actually.
So it's like cell, cell communication that's actually keeping everything in check.
Speaker A:What an interesting subject though.
And there's no answer to it yet.
So watch out.
Speaker B:No.
And it's very hard to dissect.
Right.
So there's loads of different mechanisms that go along at the same time.
I guess that's also the partially the interesting thing of comparative biology.
So studying different species and how they respond to certain things or what they show.
Like there's many routes that evolutionary biology can take to have different solutions to the same problem.
And some of them are very correlated.
You would need to manipulate them all one by one.
And then there's scaviats and the experiments that you could do.
So dissecting it fully will be very hard.
But it's a nice challenge and it's interesting and I think especially it can give us new inspiration or renewed intuition of how we look at within species biology.
Right.
So if you take this example that I just more or less like I didn't make it up on the spot, but it's like a hypothesis, right.
So cell, cell communication is more important in cancer suppression in long lived animals.
You can now go and test this.
Right.
And it can be very valuable if this is also really important in our own species because we're long lived.
Right.
To then use that so that that is what the value is of looking comparatively.
Speaker A:So while we all obviously think that DNA repair is a good thing, is there any reason to expect that more of it would eventually become too much?
Speaker B:It depends like how you activate it in terms of if you have a relatively error prone DNA repair mechanism, sometimes it might be better to leave the damage where it is and not repair it.
There's very rare situations maybe where that could be relevant.
It could potentially be cells that aren't dividing anymore.
But on the flip side of this, a lot of the a part of the literature that's looking at DNA repair and connections to health is actually finding that there's.
When your DNA is broken, there's a whole complex that starts to bind this and it starts to send out stress signals to the CEL which causes maybe actually negative effects on its own of this break being there, not the consequence of having that mutation there, but having the damage there.
So the damage signaling from this location might actually be what's detrimental to health.
So then resolving this in some way, shape or form should be pro health.
It depends a bit on the situation.
Speaker A:So you've mentioned the stress response.
So a little bit of stress response in cells is very healthy.
It's helpful to the whole system.
But can you just explain it a little bit?
What exactly is meant when you say a cell is under stress?
What does it mean and when is it a positive thing and when does it turn into a negative?
Speaker B:It can mean so many things.
That's why we like using the word stress, because it's more or less.
If you think about stress in general, it's an interesting concept.
Right.
So we're asking you need to have a stress response.
If you think fight or flight, you need to be able to do and go off and run away.
And then the general idea from the stress literature is like if you have enough chronic stress and there's loads of evidence for this that that is bad.
Yeah, for many things.
In terms of cellular stress mechanisms, there's many pathways that signal stress within the cell that activate usually coping mechanisms.
So there's.
It activates proteins that help with protein folding, it activates DNA repair.
Depends which pathway you're looking at, where this lands.
So in terms of.
But the general consensus of sort of ideas that come out, especially from the treatments that we know are pro longevity.
So signaling pathways that are pro longevity, if we manipulate them, usually it requires the stress response pathways that are also co activated.
This is not shown across many organisms, but it's most nicely shown in C. Elegans, the roundworm, that you need this stress coping mechanisms to show the actual longevity effect of the major longevity pathways.
So this all fits with the idea that a little bit of stress might be good.
We actually worked on this recently.
We find maybe the opposite.
But this is focusing on one particular stress pathway, which is the integrated stress response.
And there's many more.
But it's an interesting concept to think about.
Where should the stress response pathway be?
Probably has something to do with should it be chronically activated, it should possibly be able to respond to the intracellular environment.
That makes sense.
But then maybe also chronic activation might not be longevity.
Speaker A:Still want to stick with that a little bit.
Because your study focused on the integrated stress response, can you just identify what that is?
We have a lot of listeners that are researchers and that are biologists, we have a lot of investors that probably have no idea what exactly the difference is.
Speaker B:So the integrated stress response is a response that incorporates from different stressors to the cell.
It activates specific kinases, these are proteins that then phosphorylate a factor that goes on the DNA and actually or, and it acts in different ways that suppresses all protein translation transcription.
So it slows the cell down when there's stress.
But what it also does, it activates a transcription factor, for example, activating transcription factor 4, which is suggested or is known actually to then activate these coping mechanisms, these stress, these possible beneficial stress response mechanisms.
Right.
And because this pathway was studied in yeast and C. Elegans quite extensively, and it's also studied actually quite extensively a neurodegenerative disease, because it's hyperactivated in neurodegenerative disease.
But apart from that, in the longevity field, what people find was that activation of the downstream transcription factor and the intermediate was actually for longevity, this was in C. Elegans and it was in, in yeast.
And a lot of the stuff fits, right?
So it, it fits with this idea, maybe a bit of mild stress activation, especially this downstream mechanism that is you could say designed is the wrong word, but has the job of activating this stress response machinery that you can imagine would be pro health.
But we, so how we rolled into this field was that I saw this C. Elegans work, the yeast work, I talked to the people that did this work.
It was super interesting also because it integrates some diet response, it integrates amino acid deprivation.
So I just thought we need to like study this in the fly, that's my model organism that I like to use.
So then we can understand the downstream mechanisms.
So why are then these animals long lived if you activate the stress response, this integrated stress response.
So we started out by trying to more or less replicate what other people found in these other model organisms.
But what turned out is we actually found the opposite, right?
So we found that if we activated this pathway, flies reduced in longevity.
But then that's quite like okay, you can kill a fly genetically.
Woohoo, that's not super interesting.
What me and my student then did is she suppressed the pathway and that was pro longevity.
So this, this pathway probably important in aging because we show it and other people have shown it where, in which tissue, at what dose, in which context it needs to be suppressed is probably quite key where you get the benefits.
So there's many explanations why we would find differences from other models.
It could be that our flies in our hands are already quite stressed.
Stressed in terms of this pathway.
Right.
So they're always hyperactivated.
So this, remember this chronic activation might be bad, therefore suppression is good and further activation might be negative for them in terms of health.
There's also other reasons it could be tissue specific.
So in the paper we have some evidence that it might be tissue specific that currently has our most interest because there's quite a bit of literature in model organisms that suppression of this pathway in the brain is beneficial.
Whereas maybe what we're seeing is that might be what we're seeing in the fly.
Whereas in other words organs actually some activation might be positive.
Speaker A:So can we determine whether a protective response helps an organism recover or start causing harm?
Speaker B:Yeah, so one, so I've spoken at a couple of conferences on this work now and repeatedly people ask, and I think they're right, is could you now try and activate this pathway only briefly because maybe that is actually pro longevity.
So maybe the model you're using is actually chronically activating stress and we can dissect it.
Like one idea that's crude idea is that this pathway can also cause like apoptosis.
So like killing like self destruction of cells if it's hyperactivated.
This is probably not pro longevity.
It depends on the balance where this pathway is.
So that could also be the detrimental effect that we're seeing and we are self critical of our work.
It could also just be a dose dependent response.
Right.
So we might not be able to fine tune the mechanism such that it becomes pro longevity.
What would be super interesting for us to be able to dissect the mechanisms is if we can find a way that activation of the stress response could also be pro longevity.
On a technical note, there's some different isoforms of this transcription factor which might have different effects.
So that we should also explore and we're also currently hoping to do that.
Speaker A:So another form of stressing the body that's become super popular amongst the general population is fasting.
It's often discussed in terms of giving the body a challenge and activating protective processes.
But we need to be clear about what is actually being changed.
So when someone says that intermittent fasting slows aging, what do you need to know before one can judge that claim?
Speaker B:So for humans I think that's the new important development in biomarkers.
I agree.
If you have a good biomarker of aging, that would be one way.
I'm not sure we have great biomarkers of aging, but perhaps the second one is you can see if in humans again if these people are healthier, if these people have a longer lifespan, maybe most importantly if their wellbeing is better.
Right.
That all seems obvious, but it's not so easy to measure.
Also the risks associated with it are very hard to establish, right?
Because some risks might be actually quite long term and we don't know.
It's not the case of let's just do it, it might have no harm.
There could be harm if we, for example, we use the fly to study this extensively because we think it's super interesting.
It's not necessarily intermittent fasting, but it's just tighter restriction.
It's the oldest way that we can manipulate lifespan.
It works super well in the fly also.
If you do it, the effect is almost instant.
So mortality drops like sevenfold.
It's like crazy.
But what we did now actually, it's a while ago, but it's still relevant, is that we put flies on dietary restriction for a while and then we put them on fully fed conditions again.
So we give them what they would usually eat when they lay more eggs, when they're, you could say happiest in terms of production.
That actually caused them to be very unhealthy.
They all died very quickly.
We had this sort of refeeding syndrome which might be quite extreme, but it could be that there's accrued costs of having this state of restriction that then you might need to be quite careful of what you do after.
And we have no idea really what this would be.
That is maybe being a bit too risk averse because depending on how you do this, if eating a little bit less than you would like to eat is probably healthy.
Speaker A:That's a scary answer to everybody listening to this because yeah, we don't want to be on a restricted diet for our entire life.
But now if we start to eat normal again, we're going to literally drop like the flies in your experiment.
Speaker B:It is possible.
The fly model we use is quite extreme, right?
We switch them immediately, they can't adjust.
But the concept of it, and we're actually hoping to work on this more, is we can imagine on a restricted diet there's all these compensatory effects, right?
So for example, you have less intake of a certain vitamin or a certain mineral.
You upregulate all this intake.
Now you have a meal that has loads of this stuff in that you've just been restricted on and up regulated.
All the transport, perhaps all the floodgates are open.
You get all this stuff in that maybe you then need to excrete or it has dire costs in your body.
It's possible.
So this concept in itself is perhaps quite useful to understand what happens if you change your diet rapidly.
Also, the risk of potentially refeeding after a sustained period of diet restriction in terms of what people tend to do.
This won't be in the realm of what we expose the flies to.
And there's also no clear mouse data that would support this concept.
But the biological concept and the biological possibility is definitely there,.
Speaker A:I guess, even if it's not quite that dramatic.
But I think it's valuable information to know that if you do go on restricted feeding diet, don't just whenever you stop after a week or two, a month or two, just start eating as if you've never stopped.
So I guess it's the slow introduction of all these new foods again.
Speaker B:Yeah, yeah, perhaps that makes sense.
We need to have evidence to know that that actually makes sense intuitively.
Yes.
But who knows?
I guess the main things associated in human health are eating out of phase or eating loads of food at the time that you wouldn't normally eat loads of food.
Then again, having a varied diet is also good.
So it is a bit counterintuitive.
Right.
So we shouldn't always eat the same and habituate our system to it.
We should have a varied diet.
In epidemiology, it's associated with better outcomes, so it's a bit counterintuitive.
So we need to have the system have different nutrients at different times, or maybe not different times of day, but different across different days.
But then I'm saying you should be careful what you eat depending just reasoning from the fly data, which maybe be slightly counterintuitive.
And we don't know really, we actually generally don't know.
Speaker A:So you've mentioned epidemiology and you've done some work and examined survival after infection comparing dietary restrictions with rapamycin.
For someone who's heard the name rapamycin, because again, it's been all over social media and everything in the last couple of years.
A lot of people don't really know what to associate it with.
Why is rapamycin being studied in aging?
And what is rapamycin?
Speaker B:Okay, so rapamycin is a inhibitor of the MTOR complex which is target of rapamycin.
That's tor.
This is a big cellular hub that regulates loads of stuff.
If you want to simplify it a lot, it would be like go, no go, switch.
Right.
And it integrates loads of information.
And the main interesting part of it is Is that we know that if we suppress this complex, we've done this in flies as well, you can extend lifespan.
So that's interesting.
It's probably second to or maybe equivalent.
Depends who you talk to in terms of firm evidence in model organisms compared to dietary restriction, it's probably up there.
Right.
And it's been very helpful for us to understand possible downstream mechanisms associated with longevity.
This study you mentioned, it's like actually a meta analysis.
We did none of the work, but I'll tell you a bit of the work that's unpublished, that's maybe relevant.
So this is because we like using the literature to then design experiments, molecular experiments in the fly.
So there was this idea which in general would be if you restrict your diet, maybe your immune response would be slightly compromised because you are like energetically challenged.
There can be many reasons.
That was one reason and there were other reasons where immune response would be better if you would suppress MTOR using rapamycin.
So what my student Eleanor did was like just summarize the literature on mouse experiments that did this exact experiment and then you calculate the overall effect.
And what was interesting was that rapamycin improved the response to infection.
So less like crudely less mouse died when they were challenged with close to lethal challenge for dietary restriction.
They were slightly more vulnerable though the data was quite like heterogeneous, it wasn't super clear, but if anything they were slightly more vulnerable to infection.
What we then did, we did the experiments in the fly where we can manipulate the diet and mtoid together and we more or less replicate the same effect.
So it seems, yes, perhaps this is a general thing, but we need to do a lot more to understand this in general.
I think it's still a very valid idea to study this more to see how we can, especially in the elderly, improve possible like response to vaccine, general responses to infection.
It might still be quite relevant therapeutic there.
Speaker A:So what evidence would you want to see before treating this as a reason to use rapamycin to improve your resistance to infections and the other benefits?
Speaker B:Oh, in, in humans.
Oh, I think we.
It would be good to have more trials.
There have been some trials.
I'm not up fully up to date of what has been going on in terms of.
Would I take it?
No, just because I'm not generally risk averse.
I just think like why now if I would be under a certain challenge, maybe I would do if I was really worried.
Yeah, I would like to see clinical trial evidence probably the best way and other people have argued this is to focus on immunity or short term outcomes in populations that might be vulnerable.
The immune response thing is quite relevant because it is like so quantitative and also directly relevant.
Right.
So if we know we can ever so slightly improve immunity, this would be quite beneficial.
So then it could be translated quite quickly.
Speaker A:Yeah.
So talking again about something you mentioned a bit earlier on biological age and measuring of that biological age, telomeres, another word that has become quite popular recently in a paper, I think 10 years ago or so, you questioned whether the evidence justify treating telomere shortening as a cause of aging.
Do you still see that like that today or has your view changed on.
Speaker B:That?
Yes, I think I more or less see it the same way.
The this fun is more or less going back easy in time.
You're asking me about my paper 10 years ago, which I still think is relevant.
So what that paper was about was more or less asking whether we could use telomeres as a biomarker of aging or equated to age, biological age, like you say, in organisms where we cannot easily do this.
Right.
So it did have the.
The paper maybe have relevance to humans.
But I was triggered by studies and I was actually using this myself at the time.
Telomeres in wild populations where some authors were equating a shortening of tirami length to faster aging.
So maybe it's actually a bit equivalent to now with the clocks, like the epigenetic clocks we equate to slowing down.
Just for shorthand, we say it slows aging, but does it now?
Right.
Because we have no clear direct experimental evidence, although it might be coming, that this is causally related longevity.
So when I reviewed the literature at the time, just because also was interested, there were so many things contradicting this idea that telomeres are central to human longevity or other longevity, that I doubt it was that important.
Right.
So it was more or less saying, are we actually sure we can equate this a telem is shortening to faster aging?
I would say very likely not.
This doesn't mean that in certain contexts, in certain cell types.
And so like this is a bit of a boring disclaimer.
Again, it might be important, right?
There is some evidence that yes, it could be important.
Whether it's a great biomarker for aging.
I would say no.
Why and we know this as well from epidemiology, that it isn't actually a biology great predictor.
The, the question one can maybe ask or maybe keep in mind is that if we have something that's very, very intuitive.
Right.
So people Explain the telomeres as like shoelaces running down and like it shortens and it ticks and it does this and that.
If it's one on one and it seems too simple, sometimes it's true, sometimes it actually is the mechanism because it seems so like clear, key and central.
Also, sometimes it's not.
And that it's easy to explain sometimes lets us scientists as well, and myself included, I can say I haven't discovered where this has happened often.
But it, I'm sure it will happen for myself that you make this intuitive assumption, you think, oh, this all makes sense, then you move on and you start equating this idea to something you actually haven't measured.
And then you keep moving on and you forget some of the assumptions you made.
It's very common.
And I think this just happens a lot, which is fine.
We just need to stay aware.
Speaker A:Yeah, we all like easy and rational answers.
So that's.
I guess that's human nature.
But so what is telomere dysfunctional shortening then causing in the body if it's not aging or whatever people want to call it?
Speaker B:Right.
It's an interesting question.
So for me, there's certain situations where your telomeres shortening might signal that something is wrong with your cell.
So you need to do certain things.
This could be arrest cell division.
That's a valid mechanism.
It happens.
Does this directly equate to aging?
No, but it's a valid, important biological mechanism so that the biology is definitely there.
It's definitely important.
If it's important, you could also ask, is it important in normal wild type longevity?
So this is just an example.
And with all these things, it's a bit of a gray area.
It depends where you are on this debate.
And I'm not saying we shouldn't study telomeres in aging at all.
I'm not saying that at all.
I'm saying, sure, still study it, it can still be interesting.
But the, the idea, for example, that telomeres are key in mouse longevity.
They have super long telomeres and actually only start seeing the effects if they're really, really shortened to a degree that you would normally not observe.
And this is probably also the same in human.
It's hard to directly test.
But there was this hypothesis that if it reaches a certain length, then you would die.
If you analyze the data with that crude assumption, it doesn't seem to be true.
Again, this might like it seems boring, all these disclaimers, but it's important again, it could be that in certain cell types or certain chromosomes, or certain loss of telomeric DNA or certain signaling that's coming from telomeres when they're damaged can actually be quite important.
But we don't know.
Speaker A:Definitely.
I mean, that just shows that the relationship between telomeres and cancer does complicate the idea that longer is always better.
I love it.
Sometimes the simple basic answer is what we need.
Speaker B:That's it.
But it's analogous to the next thing I'm going to say.
Whereas if we have a biomarker that we then put into one number, we more or less know it will not capture the complexity that we want to possibly capture, but it is intuitive again and it's handy.
And you have a number that tells us something, and it will probably tell us something additive to chronological age.
So, like when your birthday was.
Because we know there's heterogeneity and how we age, whether there's one marker that captures everything, probably no.
But we can work, and we are currently not doing that, but other labs are doing it.
Where you have such a good way of looking at an organism in a systems biology perspective that, no, you don't distill one number, but you have such a good integration of all data that perhaps you can capture aging very well, which may allow us to understand pro longevity interventions, heterogeneity as well during the aging process.
But this is more like an experimental tool rather than having a biomarker that tells you something directly.
I think once you take multimodal data and you put it into one number, you always lose information.
That's in the sense, the point of doing it right, because then it becomes interpretable, but you just need to stay aware.
So if.
If you think, like, is that possible?
I would say no.
But if you want to identify, like, people that are aging super fast, there might be a small proportion of the population that has a certain signal that you can always identify.
I think that could be possible.
And that's what we're doing with like, disease diagnosis, right?
So we know if people have X, y, Z, they have this, we treat them.
Bam.
Similar things could be going on with aging, but aging in the general population, to identify a general number for everyone, I doubt that will be.
It might be a bit informative, but it won't tell us everything.
Speaker A:So I've mentioned a paper that you've written 10 years ago.
Now, I want to mention a paper that's super recent, and in that paper you looked at fat molecules in our cells and what happens to their length as we age.
Tell us about that.
And what does longer mean?
And.
Well, tell us about that paper.
Speaker B:Oh, yeah.
Again, this was collaboration, so this is from Georges Janssen, and he led the study in Amsterdam.
And we more or less provided samples and some experimental data on flies that he could then test his hypothesis on.
And what he finds is that in general, the lipid profile, if you look at all lipids together, lipids tend to elongate with age, and it tends to associate also with interventions associated with aging.
Why it's interesting and why possibly, yes, I should also do some more work on it, but there's so many things to study.
But why it's interesting and why I think it's valuable is that there's a new sort of idea of then looking at what aging is.
Right?
So this is a whole new modality of how lipids are regulated.
We knew from all the work, for example, this just tangently relates, but it's possibly important that how fluid or how rigid the membrane is of a cell can actually be quite important.
And it changes with age, how this is regulated.
And he shows in his paper that if you manipulate this using C. Elegans, you can actually show it's partially causal.
So we should do this in other models.
And then maybe it's a general sort of facet of aging that happens in terms of.
If you think is this now again relevant for human health?
The question is it could be.
It could also not be right.
If you think of aging, there's all these multiple modes that are integrating and all combine and the output is health.
It could be this is not really a limiting factor in human age.
And although George's like data that it's also all the same in humans.
So it's well, possible, but we need to study it further to really know if it is.
Speaker A:But how do you decide whether a pattern like that is contributing to aging or simply just accompanying it?
Speaker B:Yeah, so that's a very good question.
So I think that is actually coming back to the first question you asked me.
Why are we studying animals?
Right.
Because we can manipulate very precisely these mechanisms in model organisms mostly, and then study what happens.
We can also take human cells and study the mechanisms in human cells.
This now allows us to go from a correlation to a causal effect.
Right?
So we can find that if we manipulate the gene that orchestrates this lipid length, we can find that, yes, it's causally related in C. Elegans.
This doesn't mean it does replicate in many organisms.
But there's a clue, right?
There's big, big, big value Though, in correlative data.
So it's just accompanying the aging process.
And that is because if we don't have the correlation, it's maybe unlikely that the causal effect is going on.
Right.
So it gives a very important information telling us about where aging might happen, where it might not happen.
If you think of Georges Purple again as an example, the C. Elegans data alone, without the human sort of correlative data, which is very compelling, will actually not maybe give other people the idea to then study it in other models or even take it clinical work eventually.
Speaker A:So in this study, I think it found that the balance between shorter and longer molecules matter, rather than simply the amount of overall fat in the cells.
So wouldn't it be easier just to hear it, like, oh, shorter fats or longer fats, what does it mean for the general population that it's not one isn't better than the other?
It's the combination that matters.
Speaker B:If you think in general, in biology, these things are common where, if you think about the things that break, and we recently have done some sort of thinking about this, where we think about aging as being more a loss of regulatory processes that then push the system into a certain direction.
Right?
So if all regulatory processes are working like they should be, health is maintained optimally.
And what we see during aging is the breaking of all biology, right?
Everything is falling apart.
It's quite depressing to think about it, but that's what's happening.
And what maybe is happening first is the regulatory mechanisms that maintain homeostasis in a very broad sense of the word.
Right.
So this might mean we see in important biological domains as sort of drift of this regulatory loss.
We can measure this in correlative space.
And it might be if we then improve the regulation or improve sort of how you now mention this ratio, that then this could be polongevity.
Why that is exactly.
We need to do cell biology experiments to find what's actually happening.
But this concept is probably quite general.
Speaker A:So what would be the next experiments needed to turn this from an interesting finding into a stronger treatment possibility?
Speaker B:So with anything, I think usually the general steps are we move to another model organism.
This doesn't necessarily have to be mice.
There's other model organisms, there's certain.
Achillifish is a good model, for example, Flies are a good model, for example, we could manipulate the same gene as in this lipid paper.
We could do the same in the fly and see if the same effect is there.
Also measure the correlative metrics.
So I think in terms of if the, the idea of doing that is if you go across different species, that the or different genotypes is one other way.
Right.
So you can generalize across different genotypes perhaps.
And this has sometimes happened with certain interventions that it was just rescuing like not necessarily genetic defect, but the genetic vulnerability of a certain genetic line that people were using of any model organism.
So you should expand the genetic range.
If you go to different species, this allows you to say, okay, probably this is a general mechanism that score to our shared biology that then maybe is worth intervening in.
In contrast though, it could also mean that some of these effects are actually not that relevant in long lived organisms.
Right.
That approach is the big sort of assumption that what we do in short lived model organisms or even in cell culture has direct relevance to human, which in many cases it might not be.
So it's worth thinking about the comparative biology in that sense, why you want to do it.
In terms of fascination for biology, that's fine.
You can study anything and ultimately it will be relevant in terms of human biology.
Sometimes going from maybe disease or maybe from a genetic disease or predisposition for certain things will actually be quite relevant.
But I don't do any human work.
But I think when I see human work, I think that is where a lot of the progress is.
So a risk is if we take the stuff from model organisms and like, okay, we just apply directly to humans.
Yeah, it could work in instances it might also not work or be detrimental.
Detrimentals may be risk averse.
Speaker A:I like that.
Or it may be detrimental.
Yeah,.
Speaker B:I just need to put this in here.
Speaker A:It's a fine line.
It's a fine line.
I can see you working with flies and worms and all that because for you there's no hard line.
It could, it couldn't work.
It's all over.
Speaker B:The main reason also to work with flies is that we can measure the ultimate consequence of aging, which is lifespan.
Right.
So that indicates everything.
It does mean that integration is sensitive to loads of interventions.
But it's a good starting point to find important biology.
Yeah, I think.
Speaker A:So.
Looking into your crystal ball, what strands of research do you think will have an impact, a real impact in the next few years.
Speaker B:On human longevity or just in terms of longevity field or anything,.
Speaker A:Whatever.
Name things that we can get excited about.
Speaker B:So personally, for my own research, I'm very, very excited by the idea that we recently put out where we like this is thinking about regulation in biology.
So any process you need to regulate, you need to have induction and you need to have negative feedback.
And we think this breaks during aging and that causes possibly a lot of aging that we see.
What we are trying to do is now synthetically induce more regulation inducing like synthetic genetic feedback loops that now make the organism able to regulate longer.
This is completely artificial and we have some clues now that this might work.
So I think that focus for me personally would be very exciting.
So we had have this paper out.
There's a very cool like paper now out in nature perspectives that actually takes a part of this sort of asymmetry that we call it and applies it how epigenetic aging works, which is beautiful.
And that's how science sort of works.
If you have this synergy, then perhaps this is a new idea that can really spur on how we think about treating and looking at aging.
That would be really cool.
So for me personally, I would like to see that in terms of the wider longevity space.
I think just the, the big data that we have and now the tools to understand the big data is amazing.
Right.
So we'll have ways of viewing data that we have not been able to do before, like with the use of AI, but also the use of just having those big data sets and across different modalities and more generally, just the excitement in the longevity space should hopefully lead to more funding into blue skies research.
Because this is where everything starts, right?
And the more we have of that, the more exciting it is for me because I just love seeing new biology in the aging space.
Right.
So that's what excites me.
That gets me going in work every day.
So yeah, I think that's my answer.
Speaker A:It's exciting.
Prospects ahead.
We like that.
Thank you so much Dr. Mira for coming on beyond longevity.
Before I let you go, we have five rapid fire questions I ask all my guests.
What is the single best piece of advice you would give your younger self?
Speaker B:Focus.
Speaker A:Name one habit everyone should adopt for a longer, healthier life.
Speaker B:Socialize.
Speaker A:I like it.
You really give the rapid firework.
It's just a word.
If you weren't in longevity science, or science as a broader word, what career would you have chosen?
Speaker B:I think something like manual labor type thing.
I enjoy doing things just like making stuff.
Speaker A:What microdose habits.
5 Minute routine of small daily action yields outsized longevity benefits.
Speaker B:I would say weightlifting.
Speaker A:What's the craziest longevity myth you've encountered and is there any truth to it?
Speaker B:The original it's myth.
Like it's interesting where you have like the association with how many heartbeats an animal has and its longevity so this scales beautifully across species, but we know this is not true, right?
So within species, this is not true.
Across species it is.
So, yes, that's maybe a myth.
You shouldn't slow down your heartbeat to necessarily live longer.
It's not a finite amount of beach you have that's left.
Speaker A:Well, thank you so much once again, really.
It was super interesting.
And yeah, thanks for making the time.
And don't forget your afternoon session.
Speaker B:Yeah, yeah, my pleasure.
Yeah, my pleasure.
Thank you.
Speaker A:When I asked Dr. Mira why we age, he asked me to think about a rock.
A rock can sit there for centuries without doing anything.
But a living body has to keep working while it repairs itself.
Think of the whale in those terms.
And 200 years is a long time to keep doing both.
Can we help our bodies keep doing that work for longer?
Take fasting.
You set out to change when you eat, but you might end up also changing how much you are eating.
If there is a benefit, it matters which change helped.
And before we call it slower aging, it matters what we measure.
A lower number on a biological age test is one result.
What we really want to know is whether we will stay healthier as we get older.
Thank you so much for joining me today on Beyond Longevity.
Please rate, review and subscribe.
It.
Sa.
